89bio Inc (ETNB) Live Share Price, Invest From India

89bio Inc Stock Performance

as on October 30, 2025 at 1:29 am IST

Day's Low
Day's High
$14.82
Day's Price Range
$14.87
$14.86
0.27%
Downside
0.07%
Upside
52 Week's Low
52 Week's High
$4.16
52-Week Price Range
$15.06
$14.86
72.01%
Downside
1.35%
Upside

89bio Inc share price movements today

Previous Close: $14.84
Open: $14.84
Volume: 18.3M
Day's Low - High: $14.82 - $14.87
52 Week Low - High: $4.16 - $15.06

89bio Inc Historical Returns

1 Month Return: 0 %
3 Month Return: 0 %
1 Year Return: 0 %
3 Year Return: 0 %
5 Year Return: 0 %

89bio Inc Stock Fundamentals & Key Indicators

Check 89bio Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

EPS (TTM)

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

PEG Ratio

EBITDA

Revenue (TTM)

Profit Margin

0.00%

Return On Equity TTM

0.00%

89bio Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of 89bio Inc with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %
89bio Inc	BUY	$-	NA	NA	0.00%
Alnylam Pharmaceuticals, Inc.	BUY	$57.4B	236.95%	1448.53	1.36%
Beone Medicines Ltd	NA	$35.7B	NA	NA	-3.89%
Vertex Pharmaceuticals Incorporated	BUY	$105.8B	88.96%	29.32	31.35%
Regeneron Pharmaceuticals, Inc.	BUY	$67.7B	11.91%	15.43	32.13%

Analyst Recommendation on 89bio Inc Stock

Based on 16 analysts

BUY

81.25%

Buy

18.75%

Hold

0.00%

Sell

Based on 16 analysts, 81.25% of analysts recommend a 'BUY' rating for 89bio Inc. Average target price of $29.3

89bio Inc Share Price Target

Get share price movements and forecasts by analysts on 89bio Inc.

What analysts predicted

49.28%UPSIDE

Target Price

$29.3

Current Price

$14.86

Analyzed by

16 Analysts

Target

$29.30

89bio Inc target price $29.3, a slight upside of 49.28% compared to current price of $14.86. According to 16 analysts rating.

89bio Inc Quarterly Profit & Loss

All numbers in Millions USD

	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025
Total Revenue	-	-	-	0	-	-	-	0	-	-
Gross Profit	0	0	0	0	0	0	0	0	0	0
Operating Income	-	-	-	-	-	-	-	-	-	-
EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Expense	-	-	-	-	-	-	-	-	-	-
Depreciation	-	-	-	-	-	-	-	-	-	-
Income Before Tax	-	-	-	-	-	-	-	-	-	-
Income Tax Expense	-	-	-	-	-	-	-	-	-	-
Net Income	-84	-38	-34	-40	-51	-47	-149	-118	-71	-111
Net Profit Margin	0.00%	0.00%	0.00%	-17194.44%	0.00%	0.00%	0.00%	-563590.48%	0.00%	0.00%

89bio Inc Annual Profit & Loss

All numbers in Millions USD

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Revenue	-	-	-	-	-	-	-
Gross Profit	0	0	0	0	0	0	0
Operating Income	-	-	-	-	-	-	-
EBITDA	-	-	-	-	-	-	-
Interest Expense	-	-	-	-	-	-	-
Depreciation	-	-	-	-	-	-	-
Income Before Tax	-	-	-	-	-	-	-
Income Tax Expense	-	-	-	-	-	-	-
Net Income	-16	-57	-49	-90	-102	-142	-367
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Global Institutional Holdings in 89bio Inc

Funds	Holdings
HHG PLC	14.02%
RA Capital Management, LLC	13.41%
Suvretta Capital Management, LLC	9.58%
BlackRock Inc	7.13%
Deep Track Capital, LP	6.41%

See all

Insights on 89bio Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Best in 1 Year
In the last 1 year, ETNB has outperformed top 5 stocks with highest market-cap in its industry
POSITIVE IMPACT
Price Rise
In the last 3 months, ETNB stock has moved up by 56.2%
NO EFFECT
Against Peers
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 132.4% return, outperforming this stock by 77.0%

About 89bio Inc

89bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The Company’s lead product candidate, pegozafermin, a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is being developed for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). Pegozafermin is engineered to protect against proteolysis and reduce renal clearance and optimize its potency, enabling the potential use of a lower dosage/dose. Pegozafermin has been optimally constructed with two mutations via substitutions with natural amino acids at site-specific positions (173 and 176) toward the C-terminus end of the hormone.

Organisation	89bio Inc
E-voting on shares	Click here to vote

FAQs

What is 89bio Inc share price today?

89bio Inc share price today is $14.86 as on October 30, 2025 at 1:29 am IST at the close of the market. 89bio Inc share today touched a day high of $14.87 and a low of $14.82.

What is the 52 week high and 52 week low for 89bio Inc share?

89bio Inc share touched a 52 week high of $15.06 on September 18, 2025 and a 52 week low of $4.16 on April 9, 2025. 89bio Inc stock price today i.e. October 30, 2025 at 1:29 am IST is closed at $14.86,which is 1.33% down from its 52 week high and 257.21% up from its 52 week low.

How to invest in 89bio Inc Stock (ETNB) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for 89bio Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in 89bio Inc Shares that will get you 0.1009 shares as per 89bio Inc share price of $14.86 per share as on October 30, 2025 at 1:29 am IST.

What is the minimum amount required to buy 89bio Inc Stock (ETNB) from India?

Indian investors can start investing in 89bio Inc (ETNB) shares with as little as ₹88.566 or $1 (as of November 7, 2025 at 1:17 pm IST) using the INDmoney app.
For example: If you want to invest $10 or ₹885.66 in 89bio Inc stock (as per the Rupee-Dollar exchange rate as on November 7, 2025 at 1:17 pm IST). Based on 89bio Inc share’s latest price of $14.86 as on October 30, 2025 at 1:29 am IST, you will get 0.6729 shares of 89bio Inc. Learn more about fractional shares .